Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | RUNX1 | Q01196 | 1/20 | 0.58 |
| ▸ | CBFB | Q13951 | 11/20 | 0.56 |
| ▸ | METAP2 | P50579 | 3/20 | 0.56 |
| ▸ | METAP1 | P53582 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PKM | P14618 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | GCK | P35557 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2551982 | 0.95 | NPC1 (0.58) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL14906668 | 0.86 | CBFB (0.54) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL179142 | 0.85 | NPC1 (0.69) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL15780004 | 0.82 | CBFB (0.75) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL179149 | 0.81 | NPC1 (0.63) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL1656372 | 0.79 | GCK (0.63) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL17492287 | 0.78 | CBFB (0.64) | NPC1RAB9ARUNX1CBFBMETAP2 | |
| SCHEMBL1657642 | 0.78 | GCK (0.62) | CBFBGCK | |
| SCHEMBL1656346 | 0.76 | GCK (0.71) | CBFBGCKCYP3A4CYP2C19 | |
| SCHEMBL1657222 | 0.75 | GCK (0.50) | NPC1RAB9ARUNX1CBFBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE46943-E1 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2018-07-10 | — | — | US | disclosed |
| EP-2556058-B1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INST (AU) | 2017-06-14 | — | — | EP | disclosed |
| US-8999993-B2 | Radioprotector compounds and methods | PETER MACCALLUM CANCER INSTITUTE (AU) | 2015-04-07 | — | — | US | disclosed |
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2013-05-02 | — | — | US | disclosed |
| EP-2556058-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | Peter MacCallum Cancer Institute (AU) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011123890-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-10-13 | — | — | WO | disclosed |
| WO-2011123890-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | PETER MACCALLUM CANCER INSTITUTE (AU) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130109678-A1 | RADIOPROTECTOR COMPOUNDS AND METHODS | NR1H2, NR1H3, NR1I3 | NPC1 230/4885RAB9A 2599/4885RUNX1 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.